How does the NEOVACC vaccine work? Explore the first personalized DNA vaccine trial for lung cancer.
A patient with advanced non-small cell lung cancer (NSCLC) has become the first person in the world to receive a personalized lung cancer vaccine in a first-in-human clinical trial, marking a significant milestone in precision cancer treatment. ()
The international Phase 1 NEOVACC trial is being led by researchers at the University of Liverpool, The Clatterbridge Cancer Centre (CCC), and the Liverpool Clinical Trials Centre.
The study is evaluating a bespoke vaccine designed to target the unique genetic mutations present in each patient’s tumor, with the aim of helping the immune system recognize and destroy cancer cells that have escaped existing treatments.
Advertisement
First Patient Receives Personalized Lung Cancer Vaccine
The first participant enrolled in the trial has advanced NSCLC that responded only partially to immunotherapy. Researchers hope the personalized vaccine will strengthen the patient’s immune response by directing it toward tumor-specific mutations that standard therapies may have failed to eliminate.
Unlike conventional cancer treatments, the vaccine is individually designed for each patient using detailed genetic analysis of their tumor. Computational tools identify unique tumor targets, allowing scientists to create a therapy tailored to the patient’s cancer.
Advertisement
Vaccine Uses Innovative Doggybone DNA Technology
A key feature of the vaccine is its use of doggybone DNA (dbDNA), a synthetic DNA platform developed to produce personalized vaccines more efficiently.
Researchers believe this technology could significantly reduce the time and cost involved in manufacturing individualized cancer vaccines while making large-scale production more feasible if the approach proves successful.
The vaccine combines genomic sequencing with computational analysis to identify neoantigens—genetic changes unique to a patient’s tumor—and uses dbDNA technology to train the immune system to recognize and attack those cancer cells.
Advertisement
Trial Targets Patients at High Risk of Immunotherapy Resistance
Although immunotherapy has transformed the treatment of advanced NSCLC, only a subset of patients experiences long-lasting benefits. Many patients either do not respond or eventually develop resistance, allowing the cancer to progress.
The NEOVACC trial specifically focuses on patients whose tumors initially respond to immunotherapy but remain at high risk of developing treatment resistance. Researchers believe this group could benefit most from an additional immune-based strategy.
The Phase 1 study is supported by a £2.66 million grant from the UK’s Medical Research Council and brings together oncologists, immunologists, genetic scientists, NHS clinicians, and industry collaborators.
Lung Cancer Remains a Global Health Challenge
Non-small cell lung cancer accounts for the majority of lung cancer cases worldwide. Around 50,000 people are diagnosed with NSCLC each year in the UK, while the disease affects approximately two million people globally, making it one of the world’s most common cancers.
Despite advances in targeted therapies and immunotherapy, survival rates remain poor for patients with advanced disease, highlighting the need for new treatment approaches that can improve long-term outcomes.
Researchers Hope Personalized Vaccines Can Improve Outcomes
Professor Christian Ottensmeier, Consultant Oncologist at The Clatterbridge Cancer Centre and Chief Investigator of the study, said the personalized approach could offer new hope for patients whose cancers have only partially responded to immunotherapy.
Researchers also believe the use of doggybone DNA technology could become a breakthrough in producing personalized cancer vaccines more rapidly and at lower cost, making precision immunotherapy more accessible in the future.
NEOVACC Trial to Test Safety and Immune Response
As a Phase 1 clinical trial, NEOVACC will primarily evaluate the safety and feasibility of the personalized vaccine while also looking for early signs that it can stimulate an effective anti-tumor immune response.
If successful, the findings could pave the way for larger clinical trials and support the development of personalized DNA vaccines for lung cancer and potentially other solid tumors.
Researchers say the study represents an important step toward more individualized cancer treatment, where therapies are designed around the genetic profile of each patient’s disease rather than using a one-size-fits-all approach.
References:
- World first as patient receives pioneering lung cancer vaccine – (https://news.liverpool.ac.uk/2026/07/30/world-first-as-patient-receives-pioneering-lung-cancer-vaccine/)
Source-Medindia